An observational study suggests that prior metformin use may offer a protective effect against COVID-19 mortality in people with type 2 diabetes, but only for women.
People with type 2 diabetes who are treated with metformin prior to undergoing major surgical interventions may have better postoperative outcomes than those without exposure to the drug, researchers report.
Adding the DPP-4 inhibitor sitagliptin to first-line metformin therapy may delay the need for exogenous insulin among people with type 2 diabetes, researchers report.
Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.
Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.
Advisory Board member Theresa Smyth tackles an emergency case involving a type 2 diabetes patient on a new diet and treated with empagliflozin. What went wrong and how should he be managed? [Read more].
Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.
This meta-analysis of observational studies assesses the association between risk of bladder cancer and exposure to pioglitazone among subjects with type 2 diabetes [read more]. Mehtälä J et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0360-4
An observational study suggests that prior metformin use may offer a protective effect against COVID-19 mortality in people with type 2 diabetes, but only for women.
Results from an observational study suggest that the use of metformin in older patients with type 2 diabetes is associated with a reduced decline in both global cognition and executive function, and a decreased risk for dementia.
Metformin consistently causes an early reduction in hemoglobin and increases the risk for moderate anemia in patients with type 2 diabetes, a MASTERMIND consortium analysis shows.
This collection provides an overview of the epidemiology, underlying pathophysiological mechanisms, screening, assessment and management of heart failure in patients with diabetes mellitus.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
